Free Trial

GlucoTrack Q4 2022 Earnings Report

GlucoTrack logo
$0.37 -0.03 (-6.45%)
As of 02/21/2025 04:00 PM Eastern

GlucoTrack EPS Results

Actual EPS
-$9.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

GlucoTrack Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GlucoTrack Announcement Details

Quarter
Q4 2022
Time
N/A

Conference Call Resources

GlucoTrack Earnings Headlines

GlucoTrack prices offering of 2.6M shares of common stock at $1.15
$5,000 DOGE check?
Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a portion of the savings DOGE makes in Federal cuts could be funneled back to taxpayers. The media was quick to dub it a DOGE Dividend, with claims circulating that we could all receive a $5,000 check in the mail.
GlucoTrack announces completion of first in human clinical study of CGM
See More GlucoTrack Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GlucoTrack? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GlucoTrack and other key companies, straight to your email.

About GlucoTrack

GlucoTrack (NASDAQ:GCTK), a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.

View GlucoTrack Profile

More Earnings Resources from MarketBeat